We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

110 hedge funds and large institutions have $320M invested in GenMark Diagnostics, Inc in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 25

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

4% more funds holding

Funds holding: 106110 (+4)

6% less capital invested

Capital invested by funds: $339M → $320M (-$19.3M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $46K

Holders
110
Holders Change
+4
Holders Change %
+3.77%
% of All Funds
2.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
43
Reduced
25
Closed
12
Calls
Puts
$46K
Net Calls
-$46K
Net Calls Change
+$3K
Name Holding Trade Value Shares
Change
Change in
Stake
California Public Employees Retirement System
51
California Public Employees Retirement System
California
$432K +$68.3K +10,944 +18%
Barclays
52
Barclays
United Kingdom
$404K +$70.7K +11,330 +20%
AllianceBernstein
53
AllianceBernstein
Tennessee
$396K
WI
54
WrapManager Inc
California
$389K +$5.52K +884 +1%
DCM
55
Donaldson Capital Management
Indiana
$382K +$393K +63,003 New
UBS Group
56
UBS Group
Switzerland
$367K +$280K +44,902 +285%
Envestnet Asset Management
57
Envestnet Asset Management
Illinois
$357K +$20.5K +3,287 +6%
UBS AM
58
UBS AM
Illinois
$342K +$27.9K +4,468 +9%
Baird Financial Group
59
Baird Financial Group
Wisconsin
$286K
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$281K
PCMI
61
Paradigm Capital Management Inc
New York
$271K +$156K +25,000 +127%
CS
62
Credit Suisse
Switzerland
$253K +$17.8K +2,852 +7%
Ameriprise
63
Ameriprise
Minnesota
$249K +$257K +41,109 New
ONB
64
Old National Bancorp
Indiana
$231K
Manulife (Manufacturers Life Insurance)
65
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$219K
PP
66
PDT Partners
New York
$218K
LOAMU
67
Lombard Odier Asset Management (USA)
New York
$212K -$49.4K -7,920 -18%
AIG
68
American International Group
New York
$208K -$1.49K -239 -0.7%
Russell Investments Group
69
Russell Investments Group
United Kingdom
$198K +$14.7K +2,356 +8%
EGM
70
Engineers Gate Manager
New York
$193K -$54.2K -8,684 -21%
RA
71
Royce & Associates
New York
$188K -$281K -45,000 -59%
EMG
72
ETF Managers Group
New Jersey
$162K +$1.89K +302 +1%
State Board of Administration of Florida Retirement System
73
State Board of Administration of Florida Retirement System
Florida
$161K
MIM
74
MetLife Investment Management
New Jersey
$160K
Susquehanna International Group
75
Susquehanna International Group
Pennsylvania
$147K +$25.8K +4,142 +21%

GNMK Hedge Fund Activity: Q3 2019 in Review

110 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2019, worth a combined $320M — down 5.7% from $339M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GNMK positions and 12 closed out — a net gain of 5 holders — while 43 added to existing stakes and 25 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $14.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $22.4M.

  • 110 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2019, up from 106 in Q2 2019.
  • Funds reported $320M of GenMark Diagnostics, Inc stock for Q3 2019, down 5.7% quarter-over-quarter.
  • 17 funds opened new GenMark Diagnostics, Inc positions in Q3 2019 and 12 closed out, a net change of +5 holders.
  • The largest GenMark Diagnostics, Inc buyer in Q3 2019 was Morgan Stanley, an estimated $14.2M added.
  • The largest GenMark Diagnostics, Inc seller in Q3 2019 was T. Rowe Price Associates, an estimated $22.4M sold.

Based on aggregated 13F filings for Q3 2019.